ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Hormone Receptor-Positive Breast Cancer · High-risk Breast Cancer · Early-Stage Breast Cancer · HER2-negative Breast Cancer · ctDNA Monitoring · Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University People's Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (yuan peng, doctor) · 13671287670@163.com · 86+13671287670

Study leads

shu wang, doctor
Principal Investigator
Peking University People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Neoplasm · Breast Cancer · Hormone Receptor Positive Tumor

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Zhanjiang, China · Guangzhou, China

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer

Abroad (travel likely)Recruiting

Shijiazhuang, China

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Marshall, United States · Aberdeen, United States